NKTR
Nektar Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 3
Sell signal 1
Stock Price Surged Significantly
Consensus Rating "Strong Buy"
Revenue Beats Expectation
Revenue Keeps Dropping
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About NKTR
Nektar Therapeutics
A biopharmaceutical company that developing investigational medicines in oncology, immunology, and inflammatory diseases
455 Mission Bay Boulevard South, San Francisco, California 94158
--
Nektar Therapeutics was founded in California in 1990 and re-registered in Delaware in 1998. The company is a clinical-stage, investigational drug discovery biopharmaceutical company focused on the discovery and development of innovative drugs in the field of immunotherapy. In this growing field, the company is committed to creating new immunomodulators that selectively induce, amplify, attenuate or block immune responses to achieve the desired therapeutic effect.
Earnings Call
Q1/2025
Estimate EPS-0.19
Actual EPS-0.24
Estimate Revenue15.36M
Actual Revenue10.50M
Nektar Therapeutics' Q1 2025: Unraveling Contradictions on AD Trials, Placebo Expectations, and Partnership Strategies
May 19,2025 05:44
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
NKTR has released its 2025 Q1 earnings. EPS was reported at -0.24, versus the expected -0.19, missing expectations. The chart below visualizes how NKTR has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
NKTR has released its 2025 Q1 earnings report, with revenue of 10.46M, reflecting a YoY change of -51.66%, and net profit of -50.88M, showing a YoY change of -38.26%. The Sankey diagram below clearly presents NKTR's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
